Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1974 May;27(5):359–367. doi: 10.1136/jcp.27.5.359

Preparation of test cells for the antiglobulin test

Fred Stratton 1, Violet I Rawlinson 1
PMCID: PMC478127  PMID: 4604936

Abstract

Erythrocytes may be coated with blood group antibodies with or without reacting complement or sometimes apparently with complement alone. This may occur in vivo in such conditions as autoimmune acquired haemolytic anaemia, haemolytic disease of the newborn, or after transfusions of incompatible blood. It may occur in vitro also by the deliberate sensitization of erythrocytes during laboratory serological investigations.

Blood group antibodies may be of immunoglobulin types γM, γA, or γG; we have never seen γD antibodies. The presence of these antibodies on the erythrocyte surface, together with complement components or the presence of complement components alone, may be detected by the direct antiglobulin test where sensitization occurs in vivo or by the indirect antiglobulin test where there is sensitization in vitro.

Full text

PDF
359

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramson N., Alper C. A., Lachmann P. J., Rosen F. S., Jandl J. H. Deficiency of C3 inactivator in man. J Immunol. 1971 Jul;107(1):19–27. [PubMed] [Google Scholar]
  2. Bokisch V. A., Müller-Eberhard H. J., Cochrane C. G. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med. 1969 May 1;129(5):1109–1130. doi: 10.1084/jem.129.5.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. DACIE J. V., CROOKSTON J. H., CHRISTENSON W. N. Incomplete cold antibodies role of complement in sensitization to antiglobulin serum by potentially haemolytic antibodies. Br J Haematol. 1957 Jan;3(1):77–87. doi: 10.1111/j.1365-2141.1957.tb05773.x. [DOI] [PubMed] [Google Scholar]
  4. DACIE J. V. Occurrences in normal human sera of 'incomplete' forms of 'cold' auto-antibodies. Nature. 1950 Jul 1;166(4209):36–36. doi: 10.1038/166036a0. [DOI] [PubMed] [Google Scholar]
  5. Engelfriet C. P., Borne AE vd, Giessen M vd, Beckers D., van Loghem J. J. Autoimmune haemolytic anaemias. I. Serological studies with pure anti-immunoglobulin reagents. Clin Exp Immunol. 1968 Sep;3(7):605–614. [PMC free article] [PubMed] [Google Scholar]
  6. Engelfriet C. P., Pondman K. W., Wolters G., Borne AE von dem, Beckers D., Misset-Groenveld G., van Loghem J. J. Autoimmune haemolytic anaemias. 3. Preparation and examination of specific antisera against complement components and products, and their use in serological studies. Clin Exp Immunol. 1970 May;6(5):721–732. [PMC free article] [PubMed] [Google Scholar]
  7. Engelfriet C. P., Von dem Borne A. E., Beckers D., Reynierse E., Van Loghem J. J. Autoimmune haemolytic anaemias. V. studies on the resistance against complement haemolysis of the red cells of patients with chronic cold agglutinin disease. Clin Exp Immunol. 1972 Jun;11(2):255–264. [PMC free article] [PubMed] [Google Scholar]
  8. Götze O., Müller-Eberhard H. J. The C3-activator system: an alternate pathway of complement activation. J Exp Med. 1971 Sep 1;134(3 Pt 2):90s–108s. [PubMed] [Google Scholar]
  9. HARBOE M. INTERACTIONS BETWEEN 131-I TRACE-LABELLED COLD AGGLUTININ, COMPLEMENT AND RED CELLS. Br J Haematol. 1964 Jul;10:339–346. doi: 10.1111/j.1365-2141.1964.tb00710.x. [DOI] [PubMed] [Google Scholar]
  10. Jenkins D. E., Jr, Christenson W. N., Engle R. L., Jr Detection of complement components on unlysed erythrocytes from acid hemolysis and thrombin test reactions in paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1966 May;45(5):796–802. doi: 10.1172/JCI105394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kerr R. O., Dalmasso A. P., Kaplan M. E. Erythrocyte-bound C5 and C6 in autoimmune hemolytic anemia. J Immunol. 1971 Oct;107(4):1209–1210. [PubMed] [Google Scholar]
  12. Lachmann P. J., Müller-Eberhard H. J. The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol. 1968 Apr;100(4):691–698. [PubMed] [Google Scholar]
  13. MOLLISON P. L., POLLEY M. J. UPTAKE OF GAMMA-GLOBULIN AND COMPLEMENT BY RED CELLS EXPOSED TO SERUM AT LOW IONIC STRENGTH. Nature. 1964 Aug 1;203:535–536. doi: 10.1038/203535a0. [DOI] [PubMed] [Google Scholar]
  14. Müllerèberhard H. J., Dalmasso A. P., Calcott M. A. The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis. J Exp Med. 1966 Jan 1;123(1):33–54. doi: 10.1084/jem.123.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nicol P. A., Lachmann P. J. The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology. 1973 Feb;24(2):259–275. [PMC free article] [PubMed] [Google Scholar]
  16. RAPP H. J., BORSOS T. EFFECTS OF LOW IONIC STRENGTH ON IMMUNE HEMOLYSIS. J Immunol. 1963 Dec;91:826–832. [PubMed] [Google Scholar]
  17. ROCKEY J. H., KUNKEL H. G. Unusual sedimentation and sulfhydryl sensitivity of certain isohemagglutinins and skin-sensitizing antibody. Proc Soc Exp Biol Med. 1962 May;110:101–105. doi: 10.3181/00379727-110-27437. [DOI] [PubMed] [Google Scholar]
  18. Ruddy S., Austen K. F. C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol. 1969 Mar;102(3):533–543. [PubMed] [Google Scholar]
  19. STRATTON F., GUNSON H. H., RAWLINSON V. I. The preparation and uses of antiglobulin reagents with special reference to complement-fixing blood group antibodies. Transfusion. 1962 May-Jun;2:135–149. doi: 10.1111/j.1537-2995.1962.tb00212.x. [DOI] [PubMed] [Google Scholar]
  20. Stratton F., Rawlinson V. I., Chapman S. A., Pengelly C. D., Jennings R. C. Acquired hemolytic anemia associated with IgA anti-e. Transfusion. 1972 May-Jun;12(3):157–161. doi: 10.1111/j.1537-2995.1972.tb00002.x. [DOI] [PubMed] [Google Scholar]
  21. Stratton F., Rawlinson V. I. Interaction between human serum complement and normal human red cells at low ionic strength. Nature. 1965 Jul 17;207(994):305–306. doi: 10.1038/207305a0. [DOI] [PubMed] [Google Scholar]
  22. Stratton F., Rawlinson V. I. The action of the first component of complement on cells sensitized with blood group antibody. Br J Haematol. 1965 Sep;11(5):592–599. doi: 10.1111/j.1365-2141.1965.tb00104.x. [DOI] [PubMed] [Google Scholar]
  23. Stratton F., Smith D. S., Rawlinson V. I. 19S gamma M, followed by 7S gamma G anti-Jk antibodies associated with pregnancy. Clin Exp Immunol. 1968 Jan;3(1):81–90. [PMC free article] [PubMed] [Google Scholar]
  24. Stratton F. Zymosan coated particles used to prepare anti-beta-1C. Vox Sang. 1966 Mar-Apr;11(2):232–237. doi: 10.1111/j.1423-0410.1966.tb04230.x. [DOI] [PubMed] [Google Scholar]
  25. Tamura N., Nelson R. A., Jr Three naturally-occurring inhibitors of components of complement in guinea pig and rabbit serum. J Immunol. 1967 Sep;99(3):582–589. [PubMed] [Google Scholar]
  26. West C., Davis N. C., Forristal J., Herbst J., Spitzer R. Antigenic determinants of human beta-1c and beta-1g-globulins. J Immunol. 1966 Apr;96(4):650–658. [PubMed] [Google Scholar]
  27. Worlledge S. M., Blajchman M. A. The autoimmune haemolytic anaemias. Br J Haematol. 1972 Sep;23(Suppl):61–69. doi: 10.1111/j.1365-2141.1972.tb03505.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES